JD Health and Gujing Distillery Join Forces: Reshaping the Trillion-Dollar Health Industry with 'AI + Supply Chain'

On March 30, the sixth JD Wine Tasting Event was held at the Gujing Gongjiu·Nianfen Yuanjiang Themed Hotel in Bozhou City, Anhui Province. Representatives from JD Health and its global pharmaceutical and health brand partners, along with consumer representatives and other guests, gathered for a customized dinner to taste Gujing Gongjiu·Nianfen Yuanjiang Gu 20 and engage in in-depth discussions on how “AI + Supply Chain” empowers the big health industry.

At the wine tasting event, attendees jointly savored Gujing Gongjiu·Vintage Original Pulp Gu 20, a liquor renowned in the industry for its unique style characterized by “crystal-clear appearance, pure orchid-like aroma, sweet and mellow taste, and a long-lasting aftertaste.” Gujing Gongjiu has won the Gold Award at the National Famous Liquor Evaluation four consecutive times. Amidst the enjoyment of this fine brew, consensus on cooperation within the health industry continued to strengthen. Meanwhile, JD Health showcased a wide range of popular health products—including pharmaceuticals, nutritional supplements, medical devices, and consumer health gadgets—as well as a series of innovative medical and health services such as AI-powered doctors and premium health management, to lucky consumers from across China and partners in the broader health industry chain.

JD Health stated that the broader healthcare sector is a marathon requiring patience and steadfastness. Much like Gujing Gongjiu’s Vintage Original Pulp liquor, which demands time to mature, this endeavor also requires concerted efforts and shared commitment. JD has always placed high importance on the development of Anhui Province and Bozhou City. As the hometown of Hua Tuo, as well as being known globally as the “Medicine Capital” and China’s “Liquor City,” Bozhou is where traditional Chinese medicine (TCM) and liquor culture shine together. Leveraging Bozhou’s unique industrial foundations, JD Health is actively positioning itself to drive the digital and intelligent upgrading of the TCM industry, injecting new momentum into the local health sector.

The past year has been a pivotal one for JD Health, marking a significant leap forward. The company’s revenue achieved year-over-year growth exceeding 20% for four consecutive quarters, sustaining a robust momentum of steady expansion. From the initial launch and implementation of innovative drugs to the continuous expansion of medical service scenarios, JD Health has made breakthroughs across multiple business segments. Underpinning this performance growth is JD Health’s unwavering commitment to becoming“National Premier Health Steward”mission, through continuous strengthening of“AI + Supply Chain” Core Competencies, promote“Medical Care–Testing–Diagnosis–Pharmaceuticals” Full-Chain Closed-Loop Service Accelerates Implementation, transforming the traffic advantage of being the "primary gateway for online health consumption" into tangible user value, industrial momentum, and social security.

Among them,In terms of omnichannel fulfillment, JD Health continued to improve its integrated online and offline pharmaceutical and healthcare supply network, with over 100 new and specialty drugs launched for the first time throughout the year, further solidifying its advantage as a leading platform for the global debut of new drugs and health products;In terms of full-cycle professional services, continuously strengthening the closed-loop service ecosystem of “medical care–testing–diagnosis–pharmacy”; services such as at-home rapid testing and nurse home visits are steadily advancing. At-home rapid testing now covers 27 cities across China, offering more than 160 types of tests, while 21,000 registered nurses provide in-home nursing care, effectively filling critical gaps in the extension of offline medical services.In terms of all-scenario AI applicationsJD Health has always been driven by AI, promoting the genuine integration of technology into products, services, and business processes. Among these efforts, its AI doctor “Dawei” has completed hundreds of millions of interactions, with an approval rating exceeding 98%. Recently, JD Health’s self-developed medical large model, “Jingyi Qianxun,” topped the global authoritative evaluation platform MedBench, ranking first in both the medical large language model and multimodal large model categories.

In fact, leveraging its “AI + Supply Chain” capabilities, JD Health is building a set of foundational competencies in the pharmaceutical and healthcare sector that have been validated over the long term. By openly empowering and efficiently integrating upstream and downstream segments of the industry chain, it is driving the transformation of traditional pharmaceutical e-commerce into an “Intelligent Hub for Healthcare Supply Chains.” This enables innovative pharmaceutical and healthcare products to “reach the right people,” ensures consumers can “access and use them,” provides “end-to-end service support,” and accelerates distribution efficiency, truly making high-quality medical and healthcare products and services universally accessible and affordable.

Since September 2025, JD Travel has leveraged JD’s super supply chain capabilities to innovatively collaborate with hotels and liquor brands, launching the “JD Wine Tasting” IP. Backed by three key assurances—“no mandatory bundling, no hidden clauses, and fully transparent cancellation and change policies”—the initiative ensures a worry-free experience for users, from booking travel to enjoying wine and socializing. To date, the “JD Wine Tasting” events have been successfully held in six cities: Beijing, Shanghai, Sanya, Shenzhen, Guangzhou, and Bozhou. By offering consumers and partners a differentiated experience of “savoring premium wines and making friends,” it has emerged as a highly anticipated new paradigm for travel-based social engagement.